Identification and Interpretation of Longitudinal Gene Expression Changes in Trauma by Rajicic, Natasa et al.
Identification and Interpretation of Longitudinal Gene
Expression Changes in Trauma
Natasa Rajicic
1*, Joseph Cuschieri
2, Dianne M. Finkelstein







3, H. Shaw Warren
8, David A.
Schoenfeld
3, and the Inflammation and the Host Response to Injury Large Scale Collaborative Research
Program
1Pfizer Inc., New York, New York, United States of America, 2Department of Surgery, University of Washington, Seattle, Washington, United States of America,
3Biostatistics Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 4University of Rochester, Rochester, New York, United States of
America, 5University of Florida, Shands Hospital, Gainesville, Florida, United States of America, 6University of Colorado, Denver Health Medical Center, Denver, Colorado,
United States of America, 7Division of Trauma and General Surgery, University of Washington, Harborview, Washington, United States of America, 8Infectious Disease
Unit, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America
Abstract
Rationale: The relationship between leukocyte gene expression and recovery of respiratory function after injury may
provide information on the etiology of multiple organ dysfunction.
Objectives: To find a list of genes for which expression after injury predicts respiratory recovery, and to identify which
networks and pathways characterize these genes.
Methods: Blood was sampled at 12 hours and at 1, 4, 7, 21 and 28 days from 147 patients who had been admitted to the
hospital after blunt trauma. Leukocyte gene expression was measured using Affymetrix oligonucleotide arrays. A linear
model, fit to each probe-set expression value, was used to impute the gene expression trajectory over the entire follow-up
period. The proportional hazards model score test was used to calculate the statistical significance of each probe-set
trajectory in predicting respiratory recovery. A list of genes was determined such that the expected proportion of false
positive results was less than 10%. These genes were compared to the Gene Ontology for ‘response to stimulus’ and, using
Ingenuity software, were mapped into networks and pathways.
Measurements and Main Results: The median time to respiratory recovery was 6 days. There were 170 probe-sets
representing 135 genes that were found to be related to respiratory recovery. These genes could be mapped to nine
networks. Two known pathways that were activated were antigen processing and presentation and JAK- signaling.
Conclusions: The examination of the relationship of gene expression over time with a patient’s clinical course can provide
information which may be useful in determining the mechanism of recovery or lack of recovery after severe injury.
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Introduction
There has been improvement in the outcome for acute lung
injury (ALI) [1] but ALI and its sequelae multiple organ
dysfunction syndrome (MODS) remain the leading cause of
mortality after the first 24 hours post-injury [2]. These complica-
tions of trauma represent an enormous health care expenditure.
Thus, the continued investigation of the pathogenesis of ALI/
MODS remains a national research priority.
This paper is a preliminary report from the large scale
collaboration Inflammation and the Host Response to Injury
(Glue), a multi-centered study supported by the National Institute
of General Medical Sciences (NIGMS), that aims to better
describe genomic response in patients following severe injury or
burns ([3,4]). Our hypothesis was that we could find a list of genes
for which expression levels predict a patient’s clinical outcome,
and that the identification of these genes could lead to new insights
into the biology of MODS.
In a previous paper we showed that baseline gene expression
could predict future MODS and other clinical events [5]. The
predictor was a combination of thousands of gene expression
values and thus could not provide insight into specific mechanisms.
Current thinking is that mechanical tissue disruption and
cellular shock trigger a cascade of proinflammatory reactions, the
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innate immune system such that a secondary insult during this
vulnerable window provokes an unbridled inflammatory response
culminating in early MODS [6–8]. The injury also initiates events
resulting in a depressed adaptive immune response, counter
inflammatory response syndrome (CARS), that renders the patient
at risk for overwhelming infection, resulting in delayed MODS
[9,10].
We have investigated the mechanisms critical for early priming
of the innate immune system and have employed the circulating
PMN as a surrogate for this response [11,12]. Our previous work
has documented that injured patients at risk for MODS have a
remarkably consistent pattern of post-injury PMN priming;
beginning within 2 hr of injury, peaking at 6–12 hr, and resolving
by 24 hr if there are no further insults [13–15].
Although the MODS is the primary mechanism of morbidity in
the patients in this study there was often no clear period between
the end of resuscitation and the onset of MODS. For this reason
we choose respiratory recovery as a surrogate for MODS. In
addition respiratory recovery represents a positive clinical outcome
for a patient and can be viewed as a marker of an improving
overall health.
In this paper, we apply novel statistical methods [17] to identify
genes for which the expression trajectory predicts respiratory
recovery, and then we relate these genes to the networks and
pathways to which they belong.
Materials and Methods
The analysis presented in this report includes data on a subset of
147 patients admitted to one of seven participating institutions,
between November 2003 and July 2006. Our paper focuses on a
subset of 147 patients who had complete genomic profiles at the
time of our analysis. The Glue study entry criteria included patients
who had suffered a blunt trauma without isolated head injury, who
had arrived at a hospital within 6 hours of the injury, and had
either hypotension or an elevated base deficit. Subjects with
anticipated survival of less than 24 hours, significant pre-existing
organ dysfunction, or severe traumatic brain injury were excluded.
Written informed consent was obtained from all patients or their
legally authorized representative. Blood was sampled at 12 hours
and at 1, 4, 7, 21 and 28 days after the blunt trauma and was
hybridized to an Affymetrix HU133 plus 2.0 gene chip. The
details of the clinical protocol and sample processing are described
in [5]. Respiratory recovery, the primary outcome of interest in
this study, was defined as a patient’s ability to breathe on their own
after the removal of mechanical ventilation. The maximum follow-
up time was 28 days, with patients who had not recovered by 28
days treated as censored with respect to the primary outcome at
that time.
Gene expressions were extracted from oligonucleotide probes
by a perfect-match model using dChip software (www.dChip.org)
and gene expression values were log-transformed prior to any
calculations. There were several steps taken to reduce the
overwhelming dimensionality of the microarray. We first excluded
probe-sets labeled ‘Absent’ over all arrays by the Affymetrix
software. ‘Present/Absent’ labels in this technology indicate
whether a probe-set was reliably detected or not. This step
reduced the number to 48,992 probe-sets. Applying the assump-
tion that the genes exhibiting temporal changes are potentially
related to the outcome, we next excluded those probe-sets with a
‘low’ sample coefficient of variation, which we defined as having a
coefficient of variation in the bottom half of the sample (i.e., below
the sample median). This reduced the number of probe-sets to
11,461. Lastly, we performed the analysis of time-course
microarrays using the EDGE [16] and deleted those that did not
change with time. The number of investigated probe sets in the
final dataset was 4,010.
The method used to obtain a list of statistically significant probe
sets has been described previously [17]. The intention of this
method is to apply a statistical test to assess whether the gene
expression level predicts a subsequent event. In order to do this,
we need the value of this expression level from each patient who is
under observation and at ‘‘risk’’ for the event. Since this value will
usually be missing, we need the approach described in [17] to
handle the missing data. For this approach, we calculated one test
statistic for each probe set among 4,010 by fitting a straight line to
the expression level over time. We then used the estimated line to
impute the probe set expression value at each time an event
(respiratory recovery) occurred. We then calculated the difference
between the imputed value for the patient who had the event and
the mean of the imputed values for all patients who were on
ventilator immediately before the event. This difference measures
Figure 1. Kaplan-Meier plot of time to respiratory recovery.
doi:10.1371/journal.pone.0014380.g001
Table 1. Patient summary.









Injury severity score 33 (6,75)
Max. MODS score 5.6 (0.4,16.4)
ICU days 10 (1,88)
ICU vent days 7 (0,48)
doi:10.1371/journal.pone.0014380.t001
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patient who had the event is greater or less than its expected value
of the expression level if there were no relationship between the
gene expression level and the occurrence of an event. The sum of
these differences tests whether the expression levels are associated
with the occurrence of an event.
Once we obtain a set of probe-set specific test statistics, we
cannot use classical p-values to infer which probe-sets are
important because the large number of hypothesis tests we have
just done will result in an inflated type I error rate (inappropriate
p-value). Instead, we can assess the statistical significance of each
test by sorting them in descending order by their absolute value
and decide how many genes in the list were statistically significant
using a false positive ratio of 10% [18]. For this, we simulated the
distribution of these statistics under the null hypothesis by
permuting the event indicators among subjects at risk at that
time. In other words, the number of subjects with events is kept
fixed at each event time, but their event indicators are randomly
exchanged among those currently at risk [17]. When we compared
the simulated test statistics with our observed test statistics, we
found that all but 170 probe-sets were eliminated, which preserved
a false positive ratio of 10%. Thus we are accepting the fact that of
the 170 probe-sets, 17 may be associated with a false positive test
statistic [19].
Results
Table 1 shows the demographic and clinical characteristics of
the patients reported in this paper. Among 147 subjects, 11 did not
experience respiratory recovery, including six patients who died
during the study follow-up; for these 11 patients, time to recovery
was censored. Figure 1 shows a Kaplan-Meier plot of the time to
respiratory recovery. The median time to respiratory recovery was
6 days with a (2, 28) day range.
As described above, 4,010 probe-sets were evaluated for an
association with the time to respiratory recovery. Of these, 170
were identified as statistically significant when the proportion of
false positive findings is set at the 10% level. Using the WebGestalt
[20] application, the 170 probe-sets were mapped onto 135 known
genes. Of the 135 selected genes, 58 were found to be positively
related to the time to respiratory recovery, while 77 genes were
found to be negatively related to this event. Here, a positive
association between a gene and time to a recovery means that the
elevation in gene expression over the time prior to the event is
associated with a shorter time to recovery. The opposite is true for
the negatively associated genes, where elevation in gene expression
prior to the event is associated with a prolonged time to respiratory
recovery. Table 2 lists the subset of selected genes grouped by the
direction of the association to the time to respiratory response. For
Table 2. Description of a subset of selected genes found to be positively or negatively related to time to respiratory recovery.
Elevation in expression is associated with shorter time to recovery
Symbol Description GO term (biological function)
APOL2 apolipoprotein L, 2 acute-phase response
CCR5 chemokine (C-C motif) receptor 5 inflammatory response
CD244 CD244 natural killer cell receptor 2B4 cellular defense response
CREBBP CREB binding protein signal transduction
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 innate immune response
EGFR epidermal growth factor receptor MAP/ERK kinase activity
IL12RB1 interleukin 12 receptor, beta 1 antimicrobial humoral response
KIR2DL2 killer cell immunoglobulin-like receptor immune response
NINJ1 ninjurin 1 cell adhesion
PSMB9 proteasome subunit, beta type immune response
PSME1 proteasome activator subunit 1 (PA28 alpha) immune response
SAMHD1 SAM domain and HD domain 1 immune response
TAP1 transporter 1 ATP binding
TAP2 transporter 2 ATP binding
Elevation in expression is associated with longer time to recovery
Symbol Description GO term (biological function)
ALOX5AP arachidonate 5-lipoxygenase-activating protein inflammatory response
ANXA1 annexin A1 anti-apoptosis
DNAJC4 DnaJ (Hsp40) homolog heat shock protein binding
HHEX homeobox, hematopoietically expressed antimicrobial humoral response
NR3C1 nuclear receptor subfamily 3 inflammatory response
PLP2 proteolipid protein 2 chemokine binding
POLI polymerase (DNA directed) iota DNA binding and repair
S100A12 S100 calcium binding protein A12 inflammatory response
S100A8 S100 calcium binding protein A8 inflammatory response
Legend: A subset of the 58 (77) genes found to be positively (negatively) related to the time to respiratory recovery is presented in the top (bottom) part of the table.
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receptor) is associated with a shorter time to recovery.
We next examined the Gene Ontology (GO) terms corre-
sponding to our group of genes found significant by statistical
hypothesis testing. These are listed in Table 3. Figure 2 illustrates
the hierarchy for the ontology terms comprising the Response
branch of the biological process. Each node contains the number
of genes among the identified genes in our set that are
represented in that particular ontology term (this is a directed
graph, where a line indicates precedence, so that the number of
genes in a lower node is included in the total number of the
preceding node). For example, a group of 30 genes were
represented among the genes comprising response to stimulus GO
term. The six genes that were represented in the inflammatory
response GO term were ANXA1 (annexin A1), S100A8 (S100
calcium binding protein A8), ALOX5AP (arachidonate 5-
lipoxygenase-activating protein), S100A12 (S100 calcium binding
protein A12), CCR5 (chemokine (C-C motif) receptor 5), NR3C1
(glucocorticoid receptor).
The 170 probe-sets with a false discovery rate (FDR) less than
0.1 were used in the network and pathway analysis. Affymetrix
probe-set IDs were imported to the Ingenuity Pathway Analysis
(IPA) software [21]. 168 of those probe-sets were mapped to the
Ingenuity database. The identified genes were overlaid on the
genomic network from the Ingenuity database and labeled as
Focus genes. Connections for each focus gene were calculated by
the percentage of its connections to other significant genes. A
total of nine networks were found, six of which are shown in
Table 3. For each network, all genes that compose it are listed.
Focus genes are represented in bold. The remaining genes that
Table 3. Six of the nine networks found by IPA.
Networks Score Focus Functions
ALOX5AP, APP, APPBP2, ATF1, C20ORF18, CCR5, COL6A1 33 20 Gene Expression
CREBBP, EGFR, GLUL, GMEB1, GMEB2, HHEX, HOXB2 Tumor Morphology
HTR2A, IL12RB1, ITCH, JAK2, LEPR, MACF1, MGMT Cancer
MICAL1, NEDD9, NR3C1, OSMR, PIAS2, PML, PTMS, RFP
RPS6KA3, SMAD3, SNX4, SNX6, STAM2, TPSAB1
ABCD2, ANXA1, BCOR, CASP1, CASP14, CEBPG 18 13 Lipid Metabolism
CLIC4, DUSP6, FABP1, FPRL1, HDAC9, HDAC1 Small Molecular Biochemistry
HIVEP1, ICEBERG, IPO11, JARID2, KLF5, MEFV Molecular Transport
MNT, NINJ1, NUTF2, PCYT1A, PEA15, PLP2
PSMB9, PSME1, PSME2, RAN, SAMD4A, SERPINB9
SET, TGIF,TNF, UBE2E1, UBE2E3
AKAP2, AVO3, BET1L, CAMKK1, CKAP2, CTPS 17 12 Cancer
EPB41L2n, EPB41L3, FBXO9, KLC3, MARK1 Tumor Morphology
NCAM1, NET1, OAT, PCTK2, PRKAR2A, PRODH Cellular Development
RAPTOR, RNH1, RPS6KB1, SCOTIN, SRGAP2
STARD10, STK11, SYNPO2, TAP1, TAP2,T G F A
TGFB1, TP53, VDP, WARS, YWHAG, YWHAH, ZNF175
ARHGEF11, C9ORF76, CASP3, CDKN2A, CDV3, DNAJB1 17 12 Cell Morphology
F2, GAST, GPX4, GRHPR, HD, HIP1, HIP1R, HNRPDL Cancer
LAMP1, MAP1LC3B, MAPK14, MAPKAPK5, MCF2L, NUDCD3 Lipid Metabolism
PRKD2, RAB8A, RAC1, RPL7, RPS19, S100A8, S100A9
SH3GLB1, TBX2, TCOF1, TNS4, TRIO, YBX2, ZBTB10, ZNF385
AIF1, AKT3, ARHGDIA, ASPH, BST1, CD44, CNP 15 11 Cardiovascular System
CSRP1, DDX58,D T X 1 ,DTX3L, EP400, GCH1, GGT1 Connective Tissue
HLA-DMA, IGF1, IGFBP6, INSR, NFIL3, OSBPL7 Organ Morphology
PA2G4, PCNA, PDCD4, PDE3B, PGK1, PHLDA1, POLD2
POLH, POLI, PTEN, SLC20A1, SYNCRIP, TNFSF11, TRAIP, TUB
CD48, CD244, CSTA, CTSC, CYP3A, DMXL2, EXPI 13 10 Cellular Function
FOS, GAB2, GCNT1, GRIN2B, GSTA1, IL2, IL3 Cell-To-Cell Signal
IL13, IL16, IL13RA2, INS1, KCNJ15, KIF17 Hematology System
KIR2DL2, LIN10, LIN7A, LRP5, PAEP, PPM2C
PPP1R12B, PTPN22, RGD:632285, RPS7, RPS14
RPS4X, SNX3, TCF1, TNFSF4
Legend: Six of the nine genomic networks found by importing the 170 probe-sets into the Ingenuity Pathway Analysis (IPA) software. Focus genes (in bold) are genes
from the input set represented in a particular network. Score of 3 or higher indicates that there is a 0.001 probability of a network being generated by chance alone.
doi:10.1371/journal.pone.0014380.t003
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provide connections to the focus genes. For example, in the first
network, there were 20 of the genes from our input set that were
over-represented in that network relative to the size of the
network. Each network is also assigned a score, which is a
probability that the focus genes were represented in the particular
network by chance alone. A network with a score of 3 or higher
has a 0.001 probability of being generated by chance alone based
on the Fisher’s exact test. Figures 3 and 4 were created using
Ingenuity software and represent the first two networks with the
two highest scores. In these figures, shadowed boxes represent
focus genes.
We next examined whether genes found in these networks
can also be placed within known pathways. There exist large
publicly available libraries of known networks and web
application that allow for organized search and examination
of these repositories. These web-based tools allowed us to
examine further our list of selected genes and compare them to
the configurations and content of known gene pathways.
Pathways of highly interconnected genes were identified using
the equation in [22].
For example, genes HLA-DMA, KIR2DL2, PSME1, TAP1,
TAP2 were involved in the antigen processing and presentation pathway,
while genes CREBBP, IL12RB1, JAK2, LEPR, MIZ1, ARCN2,
CCR5, were involved in the JAK-STAT signaling pathway, and
genes CREBBP, PLP2, and RPS6KA3 were in the Signaling
Pathway from G-Protein Families.
Discussion
Among the genes associated with a shorter time to recovery are
IL-12RB and CREB that indicate IL-2 activation and CCR5
increase, the indicators of increased immune lymphocyte function.
The Janus family (JAK-STAT) signaling pathway plays a critical
role in signal transduction mediated by cytokine and hormone
receptors. The JAK-STAT pathway is used by interferons and
Figure 2. GO hierarchy of response.
doi:10.1371/journal.pone.0014380.g002
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These cytokines and interferons activate Janus family tyrosine
kinases (JAK kinases), which in turn activate STAT proteins. In
addition, JAKs are involved in the signal transduction pathways
that govern cellular survival, proliferation, differentiation and
apoptosis. It has been well documented in the literature that the
loss of JAK kinase function has been found to result in disease
states such as severe-combined immunodeficiency and that the
optimal JAK kinase activity is crucial for normal cellular responses
[23] of downstream signaling events. In support of this hypothesis,
it has been found that JAK kinase function is required for optimal
activation of the Src-kinase cascade, the Ras-MAP kinase
pathway, the PI3K-AKT pathway and STAT signaling following
the interaction of cytokine/interferon receptors with their ligands.
Optimal JAK kinase activity is crucial for normal cellular
responses.
Among the genes associated with a longer time to recovery is
arachodoniate acid (ALOX5AP) that metabolizes into mediators
of inflammation such as leukotrienes and prostaglandins and
other ecocinoids which are associated with immune deactiva-
tion. Leukotrienes and prostaglandins act to increase vascular
permeability and serves as chemoattractant for neutrophils. In
addition, polymerase (DNA directed) iota (POLI) on the other
hand has been reported to have enzymatic properties consistent
with that of a somatic hypermutase and suggest that poliota may
be one of the DNA polymerases hypothesized to participate in
the hypermutation of immunoglobulin variable genes in vivo
[24].
The major shortcoming of the current study is that it is based on
a mixed cell population of leukocytes and genomic changes may
reflect changes in this population. At the time of this study the
technology was not available to obtain enough RNA from sorted
cells to reliably run chips on pure cell populations. This
technological hurdle has been overcome and we will soon be able
to replicate this paper with pure cell populations.
Describing all the findings of a study such as this is difficult
because the essential output of our analysis is a list of 170 probe
sets included in the supplement. These probe sets were then
mapped into 135 genes, and the genes where identified with
networks and pathways that are also described in the
supplement. We described these networks and pathways that
are known to be associated with inflammation in order to
validate the process that was used to find the 170 probe sets.
This does not contribute new knowledge. New knowledge comes
from the further study of some of the 135 genes that are not
generally known to be related to inflammation or associations of
our findings with other work that we are not aware of. We invite
the reader to do this. A much larger data set with extensive
genomic and clinical data is available by application on our
website [3].
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